Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies

Abdolvahab, Mohadeseh Haji; Karimi, Pegah; Mohajeri, Nasrin; Abedini, Mohammad; Zare, Hamed

doi:10.1186/s12935-024-03259-8

Table 3 Studies conducted in the field of targeted drug delivery by radiolabeled nanobodies

From: Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies

Name of NDs	Antigen	Type of radiolabeling	Type of study	The mechanism of action	References
Iso-[131I]SGMIB-VHH-1028	HER2	Iso-[131I] SGMIB	Pre-clinical/ Balb/c mice bearing BT474 tumor cells	Prevent tumor progression	Feng et al. [73, 74]
Iso-211At-SAGMB-5F7	HER2	Iso-211At-SAGMB	Pre-clinical/ Balb/c mice bearing BT474 tumor cells	Tumor regression	Feng et al. [73, 74]
125I-VHH 131I- IB-Mal-D-GEEEK-VHH	HER2 HER2	Iodine125 IB-Mal-D-GEEEK/Iodine 131	Pre-clinical/ Balb/c mice bearing BT474 tumor cells	Using in radio-immunotherapy and SPECT and PET imaging of HER2 + tumors	Pruszynski et al. [75, 76]
225Ac-DOTA- 2Rs15d VHH	HER2	p-SCN-Bn-DOTA/α- irradiators 225Ac	Pre-clinical/ Balb/c mice bearing SKOV3 tumor cells	Using in radio-immunotherapy in HER2 + tumors	Pruszynski et al. [75, 76]
225Ac DOTA 2Rs15d	HER2	225Ac	Pre-clinical/ Balb/c mice bearing SKOV3 tumor cells	Strong and targeted tumor uptake in both HER2 positive brain lesions	Puttemans et al. [77]
18F-FB-anti-HER2	HER2	4-[18F] fluorobenzoate ([18F]-SFB)	Pre-clinical/ Balb/c mice bearing SKOV3 tumor cells	A radiometal labeled nbs when imaging lesions in the proximity of the kidneys	Xavier et al. [72, 78]
Iso-211At-SAGMB-5F7	HER2	Iso-[211At]SAGMB	Pre-clinical/ Balb/c mice bearing BT474 tumor cells	Targeted radiotherapeutics for the treatment of HER2 expressing malignancies	Choi et al. [79]
177Lu-1B4M–DTPA-2Rs15dHIS	HER2	177Lu-1B4M–DTPA	Pre-clinical/ Balb/c mice bearing SKOV3 tumor cells	Radiolanthanide Lutetium-177 emit radiation with an appropriate linear energy transfer for the destruction of tumor cells	D’Huyvetter et al. [80, 81, 85]
99mTc-2Rs15d	HER2	Technetium-99m	Phase I clinical trial (NCT04040686)	HER2-positive tumor imaging	Devoogdt et al. [82] Vaneycken et al. [69, 71]
68Ga-NOTA-2Rs15d	HER2	Gallium 68	Phase I clinical trial (EudraCT 012001135-31) A second phase II clinical trial (VUBAR)	A safe HER2-positive tumor imaging used as PET radiotracers	Keyaerts et al. [83] Xavier et al. [72, 78]
131I-NM-02	HER2	Iodine 131	Pre-clinical/ Balb/c mice bearing SKBR3 tumor cells	A novel technique for targeted radionuclide therapy of HER2-positive breast cancer	Zhao et al. [42, 84]
131I-SGMIB-2Rs15d	HER2	Iodine 131	Phase I clinical trial (NCT02683083) A follow-up phase I/II clinical trial (NCT04467515)	Therapeutic potential for patients who progress on trastuzumab, pertuzumab, or trastuzumab emtansine	D’Huyvetter et al. [80, 81, 85]

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com

Cancer Cell International

Contact us